This Fool has his eye on an innovative growth stock that has plunged by 80% since early 2021. But what is so special about it ...

Intellia Therapeutics (NTLA) stock falls, sending its gene editing rivals lower, as Wall Street reacts to its latest layoff ...

These moves will enable the gene-editing company to focus resources on late-stage programs as it aims to launch a commercial product by 2027, it said.

Imagine a world where the genetic code is as easy to edit as a simple copy-and-paste. This is the reality of CRISPR, a ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...

Researchers unveil how biological sex influences brain aging, revealing genetic, hormonal, and molecular mechanisms behind ...

Jennifer Doudna, a UC Berkeley biochemist who shared the 2020 Nobel Prize in Chemistry for the invention of CRISPR-Cas9 ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

Four MIT faculty members are among 23 world-class researchers who have been awarded the nation’s highest honors for scientists and innovators, the White House this week. Angela […] ...

ViGeneron GmbH, a clinical-stage gene therapy company based in Munich, Germany, shared details of two new milestones in an ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more ...